Study pulls back covers on links between glaucoma and sleep
A recent study reports that abnormal sleep patterns may be risk factors for or consequences of glaucoma.
Related Articles
Online Modules
Participants in this module will learn: ▪ Differentiating etiologies of dry eye – aqueous deficiency and evaporative dry e ye disease. ▪ Evaluation and management…
Smart Glasses Debut at CES 2025
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
Tuesday Symposium
Join your colleagues for this engaging Industry Expert Theater Symposium. Sign up to receive a reminder of this meeting in your
FDA approves Zeiss MEL 90 excimer laser
With this addition, Zeiss completes the Corneal Refractive Workflow, which already includes Visumax 800 and SMILE pro.
Cotton Swab Couching of Dislocated Crystalline Lens in Marfan Syndrome
This case report discusses use of bedside manual repositioning of an anteriorly dislocated crystalline lens in a patient with Marfan syndrome.
Aviceda Therapeutics completes $207.5 million Series C financing in support of AVD-104 for geographic atrophy treatment
The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.
FDA accepts revised supplemental New Drug Application for IZERVAY
The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration and Astellas.
RFA-EY-25-002: Advancing Vision Health Equity through Multi-level Interventions and Community-Engaged Research (R01 – Clinical Trial Optional)
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Advancing Vision Health Equity through Multi-level Interventions and Community-Engaged Research (R01 –…
Bausch + Lomb Makes Two Deals to Bolster Therapeutic Pipeline in GA and Glaucoma – Eyewire+
Bausch + Lomb announced two seperate deals to acquire early- and mid-stage therapeutic assets. First, B+L, through an affiliate, acq
Bausch + Lomb acquires Whitecap Biosciences
Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.